Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients

<b>Background/Objectives</b>: Venlafaxine has been reported to exhibit significant interindividual pharmacokinetic heterogeneity across populations, which has been linked to cytochrome P450 polymorphisms and clinical factors. This study aimed to assess the impact of pharmacogenetic (PGx) and clinical determinants on the dose-normalized venlafaxine/O-desmethylvenlafaxine (ODV) metabolic ratios (MRs) in routine clinical settings in Spain. <b>Methods</b>: 29 adult patients receiving venlafaxine were prospectively recruited through the MedeA PGx Implementation Strategy into clinical practice (Extremadura, Spain). <i>CYP2D6</i>, <i>CYP2C19</i>, and <i>CYP2C9</i> genotypes were determined using TaqMan<sup>®</sup> assays, and <i>CYP2D6</i> activity scores were assigned based on allele functionality. Steady-state trough plasma concentration of venlafaxine and ODV were measured using a validated high-performance liquid chromatography method. Dose-normalized venlafaxine/ODV MRs were compared across <i>CYP2D6</i>-, <i>CYP2C19</i>-, and <i>CYP2C9</i>-genotype-predicted metabolizer groups. The influence of demographic and clinical variables on dose-normalized venlafaxine/ODV MR was also assessed. <b>Results</b>: Significant variability in dose-normalized venlafaxine/ODV MRs was observed across <i>CYP2D6</i> (<i>p</i> = 0.019) and <i>CYP2C19</i> (<i>p</i> = 0.008) metabolizer groups. Among clinical variables, sex was significantly associated with differences in dose-normalized venlafaxine/ODV MR (<i>p</i> = 0.0006). <b>Conclusions</b>: <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and sex significantly contribute to variability in venlafaxine metabolism in patients treated in routine clinical settings. These results highlight the value of combining PGx and clinical data with drug plasma concentration measurement to optimize venlafaxine therapy within PGx implementation programs.

Authors

Institutions

Publication Details

Journal
Pharmaceuticals
Published
2026-01-26
DOI
https://doi.org/10.3390/ph19020209
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients

Idilio Gónzález-Martínez, Levin Thomas, Carmen Mata-Martín, Carla González de la Cruz et al.
Pharmaceuticals
Pharmacogenetics and Drug Metabolism
article

Influence of CYP2D6, CYP2C19, and CYP2C9 Pharmacogenetics and Clinical Factors on Dose-Normalized Venlafaxine/O-Desmethylvenlafaxine Metabolic Ratio in Spanish Patients

Idilio Gónzález-Martínez, Levin Thomas, Carmen Mata-Martín, Carla González de la Cruz, Idian González-Rodríguez, Eva M. Peñas-Lledó, Adrián LLerena
article en

Abstract

<b>Background/Objectives</b>: Venlafaxine has been reported to exhibit significant interindividual pharmacokinetic heterogeneity across populations, which has been linked to cytochrome P450 polymorphisms and clinical factors. This study aimed to assess the impact of pharmacogenetic (PGx) and clinical determinants on the dose-normalized venlafaxine/O-desmethylvenlafaxine (ODV) metabolic ratios (MRs) in routine clinical settings in Spain. <b>Methods</b>: 29 adult patients receiving venlafaxine were prospectively recruited through the MedeA PGx Implementation Strategy into clinical practice (Extremadura, Spain). <i>CYP2D6</i>, <i>CYP2C19</i>, and <i>CYP2C9</i> genotypes were determined using TaqMan<sup>®</sup> assays, and <i>CYP2D6</i> activity scores were assigned based on allele functionality. Steady-state trough plasma concentration of venlafaxine and ODV were measured using a validated high-performance liquid chromatography method. Dose-normalized venlafaxine/ODV MRs were compared across <i>CYP2D6</i>-, <i>CYP2C19</i>-, and <i>CYP2C9</i>-genotype-predicted metabolizer groups. The influence of demographic and clinical variables on dose-normalized venlafaxine/ODV MR was also assessed. <b>Results</b>: Significant variability in dose-normalized venlafaxine/ODV MRs was observed across <i>CYP2D6</i> (<i>p</i> = 0.019) and <i>CYP2C19</i> (<i>p</i> = 0.008) metabolizer groups. Among clinical variables, sex was significantly associated with differences in dose-normalized venlafaxine/ODV MR (<i>p</i> = 0.0006). <b>Conclusions</b>: <i>CYP2D6</i> and <i>CYP2C19</i> genotypes and sex significantly contribute to variability in venlafaxine metabolism in patients treated in routine clinical settings. These results highlight the value of combining PGx and clinical data with drug plasma concentration measurement to optimize venlafaxine therapy within PGx implementation programs.

PharmaceuticalsVol. 19(2)
Government of Extremadura (ES), Hospital San Pedro de Alcántara (ES), Hospital Arnau de Vilanova (ES), Centro Tecnológico Nacional Agroalimentario Extremadura (ES), Centro de Implantología Cirugía Oral y Maxilofacial (ES), Universidad de Extremadura (ES)
Openalex Percentile: Top 77%
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.